Search

Your search keyword '"N.W. Clarke"' showing total 31 results
Start Over Author "N.W. Clarke"
31 results on '"N.W. Clarke"'

6. Patient-reported urinary incontinence following radical prostatectomy for prostate cancer and its association with undergoing incontinence surgery: A national population-based study

Author

M.G. Parry, J. Nossiter, T.E. Cowling, A. Sujenthiran, B. Berry, A. Aggarwal, P. Cathcart, H. Payne, N.W. Clarke, T. Skolarus, and J. Van Der Meulen

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

7. Trends and variations in risk stratified prostate cancer management: A cross-sectional study of the National Prostate Cancer Audit database using the Cambridge Prognostic Group criteria

Author

M.G. Parry, T.E. Cowling, A. Sujenthiran, J. Nossiter, B. Berry, P. Cathcart, A. Aggarwal, H. Payne, N.W. Clarke, J. Van Der Meulen, and V.J. Gnanapragasam

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

11. PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

Author

N.W. Clarke, A.J. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, G. Procopio, J.D. Guedes, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J.Y. Joung, M. Sugimoto, O. Sartor, C. Poehlein, L. Barker, A. Degboe, and F. Saad

Subjects
Urology
Published
2023
Full Text
View/download PDF

12. 1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

Author

Á.M. Haran, Y. Jain, T. Hambrock, L.R. Murphy, A. Cook, L.C. Brown, A.P. Hoyle, A. Sachdeva, S.A. Ali, C.L. Amos, M.R. Sydes, G. Attard, M.K. Parmar, N.D. James, and N.W. Clarke

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

18. The importance of lymph node location, burden and treatment outcome in M1 HSPC: analysis from the STAMPEDE trial arms A and C

Author

Alex Hoyle, Y. Jain, M.K.B. Parmar, Nicholas D. James, Claire Amos, Matthew R. Sydes, N.W. Clarke, A.M. Haran, T. Hambrock, and Adnan Ali

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Treatment outcome, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, medicine.anatomical_structure, Internal medicine, medicine, business, Lymph node, Trial Arms
Published
2020
Full Text
View/download PDF

20. The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

Author

Alex Hoyle, Chris Parker, Nicholas D. James, Robert Jones, A. Cooke, Silke Gillessen, Martin J. Russell, G. Attard, J.S. de Bono, N.W. Clarke, Matthew R. Sydes, William Cross, David P. Dearnaley, Hassan Douis, M.K.B. Parmer, Clare Gilson, Simon Chowdhury, A.W.S. Ritchie, Adnan Ali, Malcolm David Mason, and David Matheson

Subjects
chemistry.chemical_compound, medicine.medical_specialty, Hormone sensitive prostate cancer, chemistry, Prednisone, business.industry, Urology, Prednisolone, medicine, Abiraterone acetate, business, medicine.drug
Published
2019
Full Text
View/download PDF

22. Contents Vol. 40, 2001

Author

Toshiki Koyama, Uwe Pichlmeier, Francisco García-Sisamón, P. Puri, Vitaly Margulis, Maher Chtourou, Fabien Saint, Tom Gardiner, Karl-Horst Bichler, L. Wong, J. Pryor, Francisco Pastor-Hernández, Teuvo L.J. Tammela, Manuel Gil-Salom, Kevin McCallion, Montassar Kacem, Stéphane Navarra, Kate E. Williamson, C. Dawson, P. Dasgupta, Sven Lahme, Ulrich Köhl, S. Cascio, Clément-Claude Abbou, Andras Hoznek, J. Pomerl, Heini Huhtala, Guy Vallancien, Philippe E. Zimmern, Tomohiko Koyanagi, Roland Bonfig, Walter Ludwig Strohmaier, John D. Kelly, Juha Koskimäki, Matti Hakama, Denis W. Harkin, Michael D. Melekos, Laurent Salomon, W. Hendry, A. Haq, Katsuya Nonomura, José María Martínez-Jabaloyas, Axel Feyaerts, François Giuliano, Hubertus Riedmiller, Daniel S. Blander, Zoubaier Ben Safta, Dominique Chopin, Yassine Nouira, M Murakumo, Elisabet Lindholm, H.N. Blackford, Antony Cicco, S. R. Johnston, Tobias Götz, Brian J. Duggan, Katsuya Perimenis, Harriet Törnqvist, E. Meuleman, Rafael Villamón-Fort, Peter W. Hamilton, Nobuo Shinohara, Gary E. Lemack, Bertrand Guillonneau, Ali Horchani, Elmar W. Gerharz, N.W. Clarke, Karl Weingärtner, Patrick F. Keane, Julien Allard, Pasquale Chieco, John Rietbergen, E. Colhoun, S. Sharma, Barbara Stecca, Catia Giovannini, Gero Endsin, A.G. Turner, Hidehiro Kakizaki, A.J. Freemont, Finbarr E. Cotter, S. Mattocks, Roberto Martínez-García, Gunnar Olofsson, Olof Jonsson, A.A.G. Bryden, Alessandro Bertaccini, Klaus-Peter Dieckmann, Giuseppe Martorana, N.J.R. George, Neil Anderson, and Leif Eric Olsson

Subjects
Traditional medicine, business.industry, Urology, Medicine, business
Published
2001
Full Text
View/download PDF

23. 20LBA What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses

Author

Malcolm David Mason, Mona Parmar, Christopher Sweeney, Jayne F. Tierney, Claire L Vale, N.W. Clarke, Sarah Burdett, Matthew R. Sydes, Larysa Rydzewska, Nicholas D. James, Karim Fizazi, Laurence Albiges, Bertrand Tombal, and David Fisher

Subjects
Oncology, Androgen deprivation therapy, Cancer Research, medicine.medical_specialty, Hormone sensitive prostate cancer, Endocrinology, Docetaxel, business.industry, Internal medicine, medicine, business, medicine.drug
Published
2015
Full Text
View/download PDF

24. 19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476)

Author

Mona Parmar, Malcolm David Mason, Matthew R. Sydes, John Graham, Omi Parikh, David P. Dearnaley, John Staffurth, Robert Jones, J.M. Russell, Richard Cathomas, Angus Robinson, Robin Millman, Simon Chowdhury, Melissa R. Spears, N.W. Clarke, A.W.S. Ritchie, D. Tsang, Chris Parker, Susannah Brock, and Nicholas D. James

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, business.industry, humanities, Clinical trial, Kingdom, Oncology, Clinical trials unit, Academic unit, Family medicine, Cancer centre, Overall survival, Medicine, Hormone naive, business, health care economics and organizations
Abstract

N.D. James, M.R. Sydes, M.D. Mason, N.W. Clarke, D.P. Dearnaley, M.R. Spears, R. Millman, C.C. Parker, A.W.S. Ritchie, J.M. Russell, J. Staffurth, R.J. Jones, R. Cathomas, A. Robinson, S. Chowdhury, D. Tsang, S. Brock, O. Parikh, J.D. Graham, M.K.B. Parmar. Warwick University, Clinical Trials Unit, Coventry, United Kingdom; Medical Research Council Clinical Trials Unit at UCL, Institute for Clinical Trials and Methodology, London, United Kingdom; Cardiff University, School of Medicine, Cardiff, United Kingdom; The Christie NHS Foundation Trust, Department of Urology, Manchester, United Kingdom; The Institute of Cancer Research and Royal Marsden Hospital NHS Trust, Academic Unit of Radiotherapy, London, United Kingdom; Medical Research Council Clinical Trials Unit at UCL, Patient Representative, NA, United Kingdom; The Royal Marsden Hospital, Department of Radiotherapy, London, United Kingdom; Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, Glasgow, United Kingdom; Cardiff University and Velindre NHS Trust, School of Medicine, Cardiff, United Kingdom; Kantonsspital Graubunden, Department of Oncology, Chur, Switzerland; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, United Kingdom; Guy’s Hospital, Department of Medical Oncology, London, United Kingdom; Southend & Basildon Hospitals, Department of Oncology, Southend, United Kingdom; Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Department of Oncology, Poole, United Kingdom; East Lancashire Hospitals NHS Trust, Department of Oncology, Blackburn, United Kingdom; Musgrove Park Hospital, Oncology and Haematology Clinical Trials Unit, Taunton, United Kingdom

Published
2015
Full Text
View/download PDF

25. O9 Survival with newly-diagnosed metastatic prostate cancer in the 'docetaxel era': Data from around 700 patients in the control arm of the STAMPEDE trial (NCT00268476)

Author

George N. Thalmann, Melissa R. Spears, Martin J. Russell, Nicholas D. James, Malcolm David Mason, Chris Parker, Daniel M. Aebersold, N.W. Clarke, A.W.S. Ritchie, Mona Parmar, Robin Millman, Matthew R. Sydes, J.S. de Bono, and David P. Dearnaley

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, Docetaxel, business.industry, Urology, Internal medicine, medicine, Newly diagnosed, business, medicine.disease, medicine.drug
Published
2013
Full Text
View/download PDF

27. Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly–Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial

Author

N.D. James, M.R. Spears, N.W. Clarke, M.R. Sydes, C.C. Parker, D.P. Dearnaley, J.M. Russell, A.W.S. Ritchie, G. Thalmann, J.S. De Bono, G. Attard, C. Amos, M.K. Parmar, and M.D. Mason

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2014
Full Text
View/download PDF

28. Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08)

Author

M K B Parmar, Gordana Jovic, Malcolm David Mason, John Dwyer, N.W. Clarke, George N. Thalmann, Nicholas D. James, Matthew R. Sydes, J.M. Russell, and David P. Dearnaley

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, law.invention, Hormone sensitive prostate cancer, Randomized controlled trial, law, Internal medicine, Celecoxib, Medicine, Hormone therapy, business, medicine.drug
Published
2011
Full Text
View/download PDF

29. Subject Index Vol. 40, 2001

Author

Montassar Kacem, Clément-Claude Abbou, P. Dasgupta, E. Meuleman, Matti Hakama, W. Hendry, Catia Giovannini, Bertrand Guillonneau, Maher Chtourou, Andras Hoznek, A.J. Freemont, Karl Weingärtner, Guy Vallancien, S. Cascio, Hubertus Riedmiller, Gary E. Lemack, Olof Jonsson, Michael D. Melekos, Gunnar Olofsson, Peter W. Hamilton, Gero Endsin, John Rietbergen, P. Puri, Stéphane Navarra, Fabien Saint, Teuvo L.J. Tammela, François Giuliano, Pasquale Chieco, A.A.G. Bryden, M Murakumo, Alessandro Bertaccini, Brian J. Duggan, Tom Gardiner, Laurent Salomon, C. Dawson, Ulrich Köhl, Roberto Martínez-García, Antony Cicco, Manuel Gil-Salom, Neil Anderson, Julien Allard, Elmar W. Gerharz, Walter Ludwig Strohmaier, Zoubaier Ben Safta, E. Colhoun, S. R. Johnston, Harriet Törnqvist, Ali Horchani, N.W. Clarke, Karl-Horst Bichler, Tobias Götz, Juha Koskimäki, Nobuo Shinohara, A. Haq, Rafael Villamón-Fort, Katsuya Nonomura, Dominique Chopin, Francisco Pastor-Hernández, Roland Bonfig, H.N. Blackford, Patrick F. Keane, S. Mattocks, Tomohiko Koyanagi, Toshiki Koyama, Philippe E. Zimmern, John D. Kelly, Sven Lahme, Giuseppe Martorana, N.J.R. George, Elisabet Lindholm, J. Pomerl, Denis W. Harkin, J. Pryor, Axel Feyaerts, Uwe Pichlmeier, A.G. Turner, S. Sharma, Hidehiro Kakizaki, Vitaly Margulis, Klaus-Peter Dieckmann, L. Wong, Heini Huhtala, Francisco García-Sisamón, Leif Eric Olsson, Finbarr E. Cotter, Daniel S. Blander, Katsuya Perimenis, Barbara Stecca, José María Martínez-Jabaloyas, Yassine Nouira, Kevin McCallion, and Kate E. Williamson

Subjects
Gynecology, medicine.medical_specialty, Index (economics), business.industry, Urology, medicine, Subject (documents), Medical physics, business
Published
2001
Full Text
View/download PDF

31. RESULTS OF THE FEASIBILITY STAGE OF STAMPEDE: A MULTIARM, MULTI-STAGE PHASE II/III TRIAL FOR PATIENTS WITH HIGH RISK PROSTATE CANCER (ISRCTN78818544)

Author

M K B Parmar, N.W. Clarke, Rick Popert, Karen Sanders, Malcolm David Mason, David P. Dearnaley, John Anderson, Nicholas D. James, Rachel C Morgan, John R. W. Masters, and Matthew R. Sydes

Subjects
Oncology, Gynecology, PHASE II/III TRIAL, medicine.medical_specialty, Drug trial, business.industry, Urology, Refractory Disease, Disease, medicine.disease, law.invention, Multi stage, Prostate cancer, Randomized controlled trial, law, Internal medicine, medicine, Stage (cooking), business
Abstract

Most drug trials in prostate cancer (PCa) concentrate on patients withhormone refractory disease. Drugs which work later in the disease may work better still if used earlier. STAMPEDE is an academic, investigator-initiated randomised controlled trial to test six treatment approaches for patients with high-risk localised or metastatic PCa who are commencing long-termhormone therapy (HT).

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results